Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Menza, M. Articles by Lauritano, M. Search for Related Content PubMed Citation Articles by Menza, M. Articles by Lauritano, M. Depression Parkinson's Disease

Citalopram Treatment of Depression in Parkinson's Disease: The Impact on Anxiety, Disability, and Cognition

Received July 18, 2002; revised November 26, 2002; accepted January 13, 2003. From the Robert Wood Johnson Medical School, Department of Psychiatry, Department of Neurology, Camden, New Jersey. Address correspondence to Dr. Menza, 675 Hoes Lane, Piscataway, NJ 08854; menza{at}cmhc.umdnj.edu (E-mail).

Depression in Parkinson's disease (PD) is associated with faster progression of physical symptoms, greater decline in cognitive skills, and greater decline in the ability to care for oneself. The depression in these patients is also frequently comorbid with anxiety. There are no trials that provide data on the impact of depression treatment on anxiety, disability, and cognition in these patients. In this prospective, 8-week, open label trial, 10 patients with PD and major depression, without dementia, were given flexible doses of citalopram. Depression improved significantly and was associated with significant improvements in anxiety symptoms and functional impairment. The drug was well tolerated. This is the first study that provides data suggesting that treating depression in patients with PD may lead to improvements in anxiety and functional capacity. As with all nonrandomized, open-label trials at tertiary research centers, many nonspecific factors may have influenced the results.

This article has been cited by other articles:

				B. Ravina, R. Camicioli, P. G. Como, L. Marsh, J. Jankovic, D. Weintraub, and J. Elm The impact of depressive symptoms in early Parkinson disease Neurology, July 24, 2007; 69(4): 342 - 347. [Abstract] [Full Text] [PDF]

				D. Weintraub, D. Taraborelli, K. H. Morales, J. E. Duda, I. R. Katz, and M. B. Stern Escitalopram for Major Depression in Parkinson's Disease: An Open-Label, Flexible-Dosage Study J Neuropsychiatry Clin Neurosci, August 1, 2006; 18(3): 377 - 383. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us